AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06229964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSNB + IACI
Description: Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM
Study NCT06229964 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham SSNB + IACI
Description: Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM
Study NCT06395519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-19477
Description: Oral medication taken daily
Study NCT05643326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 Hz transcranial alternating current stimulation
Description: 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
Study NCT05643326 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 40 Hz transcranial alternating current stimulation
Description: 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
Study NCT05643326 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 42 sessions of sham stimulation (5 days/week for 9 weeks)
Study NCT06292130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: refresh
Description: A theoretically-grounded, highly individualized tobacco cessation Health-Kit enabled app. Unlike existing tobacco cessation apps, refresh: 1) implements a full range of best practices in tailored health behavior change communications; 2) individualizes messaging based on the patient's clinical context using Health app data obtained through Fast Healthcare Interoperability Resources (FHIR) standard Application Programming Interfaces (API) and behavior change constructs; and 3) provides data and key insights back to the EHR.
Study NCT05500781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching HER
Description: The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in \[the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches\]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
Study NCT04957329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: Eye drop
Study NCT04957329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monoprost
Description: Eye drop
Study NCT05262010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
Study NCT05262010 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
Study NCT04649671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile health
Description: Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit
Study NCT04695886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-delivered Integrated Malaria Elimination (CIME) intervention model
Description: Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral.
Study NCT02995382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Intramuscular Transposition
Description: Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
Study NCT05456347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie and high-protein diet with the majority of protein coming from animal sources.
Description: Diet was prescribed to the participant and menus and recipes were also provided.
Study NCT05456347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie and high-protein diet with the majority of protein coming from plant sources.
Description: Diet was prescribed to the participant and menus and recipes were also provided.
Study NCT05932147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: 1. Shoulder Abduction with External Rotation exercise~2. Shoulder bridge exercise~3. Mermaid sitting exercise.~4. Standing Pilates mermaid exercise with towel~5. Rocking exercise~6. Saw Pilates exercise.~7. Bird-dog Pilates exercise.~8. Roll up exercise.~9. Cobra pose exercise.~10. Child pose exercise.
Study NCT05932147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic massage
Description: procedures of Manual lymphatic drainage program Things to know about MLD Massage~* Use only gentle pressure, just enough to see your skin move.~* Massage should not be painful.~* Do not rub your skin red.~* Do massage each day.~* Repeat each step 5 to 10 times.~* The massage should take about 15 to 30 minutes.
Study NCT04847245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg tid + Duloxetine
Description: Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
Study NCT04847245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of esketamine 0.125 mg/kg+Duloxetine
Description: Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study NCT04847245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of esketamine 0.25 mg/kg +Duloxetine
Description: Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study NCT04847245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of esketamine 0.50 mg/kg+Duloxetine
Description: Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
Study NCT04731974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 MG
Description: Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
Study NCT04731974 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
Study NCT06090162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA detection
Description: ctDNA detection on CSF and blood
Study NCT06008223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B6
Description: The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
Study NCT06008223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
Study NCT04949854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter
Description: control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
Study NCT04949854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter
Description: Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
Study NCT05717218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-protective mechanical ventilation monitored by electrical impedance tomography
Description: A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored.
Study NCT05803148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 4 times， amplitude ≥ 0.7mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
Study NCT05803148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Oral Tablet
Description: Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
Study NCT04752800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Current Transcranial Stimulation - tDCS
Description: Intervenção Ativa
Study NCT04752800 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Direct Current Transcranial Stimulation - Sham Intervention
Study NCT05036525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANBIO BarriGel
Description: an anti-adhesive product
Study NCT03634839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoring Agents
Description: Flavor of e-liquid - sweet or tobacco
Study NCT03634839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine level (36 mg/ml)
Study NCT04517383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-operative sedation
Description: Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
Study NCT04517383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine recovery
Description: Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
Study NCT05332106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet
Description: Investigational Medicinal Product
Study NCT05332106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet
Description: Climodien (Bayer plc.)
Study NCT06499662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Neurodynamics
Description: This intervention involves passive cervical movements designed to enhance vagus nerve functionality.
Study NCT06499662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided Breathing
Description: This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.
Study NCT06499662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: This intervention includes suboccipital inhibition techniques applied during the session.
Study NCT06157528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients were treated with abarelix prior to the examination
Study NCT05070832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Hyperthermia
Description: Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
Study NCT04648826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroEclipse II Breath Actuated Nebulizer
Description: Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
Study NCT04648826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
Study NCT04648826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
Study NCT04777825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback training (Symbiocenter)
Description: 12 sessions of thirty minutes. Patients will participate through several serious game associated with HRV biofeedback training
Study NCT04777825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation session
Description: Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
Study NCT04777825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychoeducation session
Description: Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
Study NCT05730998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANTHOCRAN FITOSOMA
Description: The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
Study NCT05730998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
Study NCT05780905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Auto-Injector
Description: Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration.
Study NCT05987943 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
Description: A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
Study NCT05410704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Pelvic floor muscle exercises and diaphragmatic breathing exercise
Study NCT04151901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Rehabilitation
Description: Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
Study NCT04151901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking-based rehabilitation
Description: Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
Study NCT05780905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05200845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose
Description: Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT05200845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose
Description: Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT05200845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fat Test Meal Inside a Metabolic Chamber
Description: A high-fat test meal (60% fat, 20% carbohydrate) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
Study NCT05200845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Test Meal Inside a Metabolic Chamber
Description: A high-carbohydrate test meal (60% carbohydrate, 20% fat) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
Study NCT05230745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ContraBand implants
Description: Percutaneous implantation of the ContraBand devices by right heart catheterization